htm PRESS RELEASE EdgarFilingEXHIBIT 99. We are delighted that the FDA has cleared our IND application for UCART20x22, said André Choulika, PhD, Chief Executive Officer of Cellectis. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the Company) (Euronext Growth ALCLS - NASDAQ CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that the U.
💼 Business Developments:
No specific business developments reported in this filing.
🌍 Cellectis (CLLS) - Form 6-K Filing
Filing Date: 2022-08-01
Accepted: 2022-08-01 16:30:18
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
No specific business developments reported in this filing.
📞 Contact Information: